Naiyer A Rizvi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2938313/publications.pdf

Version: 2024-02-01

79 papers	33,241 citations	117453 34 h-index	82410 72 g-index
80 all docs	80 docs citations	80 times ranked	33514 citing authors

#	Article	IF	Citations
1	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
2	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	13.9	5,183
3	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	13.9	3,776
4	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
5	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
6	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	5.1	1,269
7	Overall Survival and Long-Term Safety of Nivolumab (Antiâ€“Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
8	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	3.8	857
9	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncology, The, 2017, 18, 31-41.	5.1	845
10	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	6.0	834
11	Five-Year Overall Survival for Patients With Advanced Nonâ€'Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 2019, 37, 2518-2527.	0.8	811
12	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 853-861.e4.	7.7	725
13	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncology, The, 2016, 17, 299-308.	5.1	556
14	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	13.7	532
15	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 521-536.	5.1	486
16	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	3.4	446
17	Nivolumab Monotherapy for First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2980-2987.	0.8	444
18	Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 786-795.	5.1	419

#	Article	IF	Citations
19	Nivolumab in Combination With Platinumâ€Based Doublet Chemotherapy for First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2969-2979.	0.8	397
20	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	0.8	348
21	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine, 2019, 25, 1715-1720.	15.2	194
22	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
23	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (antiâ€“PD-L1). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10119-E10126.	3.3	180
24	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
25	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of Clinical Oncology, 2019, 37, 2746-2758.	0.8	160
26	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
27	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discovery, 2021, 11, 282-292.	7.7	132
28	Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 639-643.	0.8	122
29	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Nonâ€“Small-Cell Lung Cancers. Journal of Thoracic Oncology, 2013, 8, 1084-1090.	0.5	111
30	Combining chemotherapy with PD-1 blockade in NSCLC. , 2018, 186, 130-137.		97
31	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8032-8032.	0.8	97
32	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research, 2021, 27, 1631-1640.	3.2	70
33	Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 5358-5367.	3.2	53
34	STK11Â(LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PLoS ONE, 2020, 15, e0238358.	1.1	44
35	Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1â€“selected patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8028-8028.	0.8	44
36	Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. Journal of Thoracic Oncology, 2019, 14, 1390-1399.	0.5	40

#	Article	IF	Citations
37	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer, 2020, 147, 137-142.	0.9	37
38	Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 6196-6203.	3.2	35
39	Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.. Journal of Clinical Oncology, 2017, 35, 9082-9082.	0.8	35
40	Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8007-8007.	0.8	32
41	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e47-e57.	1.8	30
42	Phase 2 Study of Erlotinib in Combination WithÂLinsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Nonâ€“Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2017, 18, 34-42.e2.	1.1	29
43	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 225.	1.1	28
44	Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 8532-8532.	0.8	26
45	Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.. Journal of Clinical Oncology, 2015, 33, 3014-3014.	0.8	25
46	Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. Journal of Thoracic Oncology, 2019, 14, 1547-1555.	0.5	20
47	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. Journal of Clinical Oncology, 2019, 37, 9016-9016.	0.8	20
48	PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age.. Journal of Clinical Oncology, 2016, 34, 3025-3025.	0.8	18
49	Into the Clinic With Nivolumab and Pembrolizumab. Oncologist, 2016, 21, 527-528.	1.9	17
50	A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.. Journal of Clinical Oncology, 2016, 34, TPS3104-TPS3104.	0.8	16
51	Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.. Journal of Clinical Oncology, 2018, 36, 3001-3001.	0.8	16
52	Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.. Journal of Clinical Oncology, 2015, 33, 8007-8007.	0.8	15
53	Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 3007-3007.	0.8	15
54	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1â€“positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 8026-8026.	0.8	12

#	Article	IF	Citations
55	Immunotherapy for Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 383-391.	1.0	10
56	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancers. Clinical Lung Cancer, 2015, 16, 514-522.	1.1	10
57	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer, 2021, 22, 301-312.e8.	1.1	10
58	Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.. Journal of Clinical Oncology, 2015, 33, 3015-3015.	0.8	9
59	Characteristics and outcomes of lung cancer in solid organ transplant recipients. Lung Cancer, 2020, 146, 297-302.	0.9	8
60	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. Cancer Research, 2021, 81, CT163-CT163.	0.4	8
61	Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.. Journal of Clinical Oncology, 2017, 35, 3038-3038.	0.8	8
62	Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) â‰¥ 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 9085-9085.	0.8	6
63	An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. Journal of Clinical Oncology, 2018, 36, TPS3120-TPS3120.	0.8	6
64	MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, TPS9105-TPS9105.	0.8	6
65	Defining the immunologic phenotype of thymic epithelial tumors.. Journal of Clinical Oncology, 2015, 33, 7516-7516.	0.8	3
66	A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3100-TPS3100.	0.8	3
67	Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 3071-3071.	0.8	3
68	Durvalumab in â‰¥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. Journal of Clinical Oncology, 2018, 36, 9058-9058.	0.8	3
69	Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, e22093-e22093.	0.8	3
70	PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.. Journal of Clinical Oncology, 2017, 35, TPS3107-TPS3107.	0.8	2
71	Patient-reported outcomes (PROs) with first-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	0.8	2
72	A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9627-TPS9627.	0.8	2

#	Article	IF	Citations
73	A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies.. Journal of Clinical Oncology, 2018, 36, 8556-8556.	0.8	1
74	The use of immunotherapy in the first-line treatment of lung cancer. Clinical Advances in Hematology and Oncology, 2017, 15, 190-192.	0.3	1
75	Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice. JTO Clinical and Research Reports, 2022, 3, 100310.	0.6	1
76	Network meta-analysis (NMA) of immuno-oncology (IO) monotherapy as first-line (1L) treatments (txs) for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression â‰¥50%.. Journal of Clinical Oncology, 2021, 39, e21091-e21091.	0.8	0
77	Characteristics and outcomes of Latino patients with EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e13578-e13578.	0.8	0
78	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. Journal of Clinical Oncology, 2020, 38, 9623-9623.	0.8	0
79	Baseline peripheral T-cell composition in relation to radiographic phenotypes of immune-related pneumonitis.. Journal of Clinical Oncology, 2022, 40, 2545-2545.	0.8	0